Breast carcinoma

This trial tests a personalized therapy called GT201, made from a patient's own tumor-infiltrating lymphocytes (TILs). The goal is to see if these immune cells, grown in the lab and infused back into the patient, can shrink or eliminate advanced solid tumors. The study includes a…

This trial is testing an experimental therapy called IOV-5001, which uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack cancer. The study involves adults with advanced solid tumors, including non-small cell lung cancer, triple-negative breast cancer, col…

This study tests a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in 50 adults with solid tumors. The goal is to see if the vaccine is safe and triggers an immune response against the cancer. Participants must have good organ function and …

This study tests an experimental drug called ATX-898 in people with advanced solid tumors that have spread or cannot be removed by surgery. The trial has two parts: first, ATX-898 is given alone to find the safest dose; second, it is combined with other anti-cancer drugs to see i…

This trial is testing an investigational drug called SHR-8203, given as an injection, in people with advanced or metastatic solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to find the safest dose, understand ho…

This trial tests whether a multimodal prehabilitation program—combining exercise, nutrition, and psychological support—can improve outcomes for patients with tumor-related bowel obstruction. Participants are randomly assigned to receive either this program plus postoperative immu…

This trial tests whether adding semaglutide to structured lifestyle counseling improves heart and blood vessel health in postmenopausal breast cancer survivors with obesity who are taking an aromatase inhibitor. Participants will receive either semaglutide or a placebo, along wit…

This study offers continued access to tucatinib, an oral targeted therapy, for people with HER2-positive cancers (including breast, cervical, and lung) who were already benefiting from the drug in a previous Pfizer-sponsored trial. The main goal is to monitor long-term safety and…

This phase 2 trial is testing a two-step treatment approach for people with advanced HER2-positive breast cancer. First, participants receive an induction therapy with trastuzumab rezetecan. If the disease does not progress, they then move to a maintenance phase combining trastuz…

This early-phase trial is testing a personalized cancer vaccine called BreakVax, designed from each patient's own tumor, in combination with immunotherapy and chemotherapy for advanced triple-negative breast cancer. The goal is to see if this multi-pronged approach can safely boo…

This trial tests whether simple reminders—sent to patients' phones and to their care teams—can increase the use of alcohol screening and brief counseling (SBIRT) during cancer care. About 315 adults with cancer across four clinics will take part, with some clinics using the remin…

This phase III trial is testing whether adding everolimus to trastuzumab rezetecan helps people with a specific subtype of triple-negative breast cancer (called luminal androgen receptor) live longer without their disease progressing. The study enrolls adults with advanced or met…

This trial is testing whether treating only part of the breast with radiation is as effective as treating the whole breast in women with early-stage, low-risk breast cancer. Participants are women aged 40 and older who had breast-conserving surgery and did not have a sentinel lym…

This trial is testing whether a special PET scan can help predict how well the drug elacestrant works in people with a certain type of advanced breast cancer (ER-positive, HER2-negative) that has not responded to prior hormone therapy. All participants will take elacestrant daily…

This phase 2 trial investigates whether immune checkpoint inhibitors—medicines that help the immune system attack cancer—can be effective when used off-label for different types of malignancies. Adults with cancer whose doctor is considering such treatment may join. Participants …

This trial is testing an experimental therapy called CRG-150, which uses a patient's own immune cells that have been gene-edited to potentially fight cancer. The study includes adults with advanced HR-positive/HER2-negative breast cancer, triple-negative breast cancer, or prostat…

This phase 2 trial is investigating whether adding an experimental drug called retlirafusp alfa to standard chemotherapy or to another drug called fuzuloparib can improve outcomes for people with triple-negative breast cancer (TNBC). The study includes two groups: one with early-…

This early-stage trial is testing an investigational drug called BR113 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive BR…

This early-stage trial is testing an experimental drug called TQB6426 in people with advanced cancers that have not responded to other treatments. TQB6426 is designed to seek out a protein called GPC3 on cancer cells and deliver a chemotherapy-like payload directly to them. The s…

This trial is testing whether a combination of drugs—inavolisib plus fulvestrant, with or without palbociclib—is safe for people with a specific type of advanced breast cancer (HR+, HER2-negative) that has a PIK3CA mutation, and who also have type 2 diabetes. The main focus is on…

This early-stage trial tests a personalized cell therapy for adults with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a patient's own tumor, grow more of them in the lab, and then infuse them back after a short course of che…

This phase 3 trial is testing whether giving four cycles of chemotherapy combined with targeted therapy (trastuzumab and pertuzumab) before surgery works as well as the standard six cycles for people with intermediate-risk HER2-positive breast cancer. The goal is to see if a shor…

This phase 3 trial tests whether a combination of sacituzumab govitecan (Trodelvy) and pembrolizumab (Keytruda) works better than standard chemotherapy before surgery for stage II-III triple-negative breast cancer. About 765 participants will be enrolled. The study aims to improv…

This Phase II trial will test whether adding a live biotherapeutic product called MO-03 (a type of probiotic) to standard chemotherapy and the immunotherapy drug pembrolizumab can improve outcomes for 50 people with early-stage triple-negative breast cancer. Participants will tak…

This trial investigates a new drug called GEN1119 for people with certain solid tumors that have not improved with standard treatments or for whom no standard treatment exists. The study is divided into parts: first, to find safe and effective doses, then to test those doses in m…

This phase 2 trial is testing whether adding an investigational drug called ivonescimab to standard chemotherapy before surgery can improve outcomes for people with triple-negative breast cancer. Ivonescimab is a bispecific antibody that works in two ways: it helps the immune sys…

This phase 2 trial is testing whether adding anlotinib to a combination of culmerciclib and endocrine therapy can control disease in people with HR-positive, HER2-negative breast cancer that has spread to the brain. The study enrolls adults with newly diagnosed or progressing bra…

This early-stage trial tests an experimental medicine called BI 3822971 in adults with advanced or metastatic solid cancers, such as lung, head and neck, breast, esophageal, bladder, vulvar, or cervical cancer, who have no standard treatment options left. The goal is to find out …

This trial explores whether people with early-stage triple-negative breast cancer and high levels of tumor-infiltrating lymphocytes (TILs) can safely skip a class of chemotherapy drugs called anthracyclines, which are effective but can harm the heart. Participants receive 12 week…

This study tests a new drug, prifetrastat, combined with fulvestrant for people with advanced HR+/HER2- breast cancer that has stopped responding to standard hormone therapy and CDK4/6 inhibitors. About 51 participants will receive the combination to see if it can shrink tumors o…

This trial is testing whether a new dosing algorithm can help people with a genetic trait called Duffy-null get the full benefit of chemotherapy. Many people of African or Middle Eastern descent naturally have lower white blood cell counts (Duffy-null neutropenia), which can lead…

This phase 2 trial tests whether alternating two targeted chemotherapy drugs—sacituzumab govitecan and trastuzumab deruxtecan—can help people with HER2-low triple-negative breast cancer that has spread. About 260 participants will be randomly assigned to receive either the altern…

This trial is testing an experimental drug called GB268, a tri-specific antibody that targets three key pathways involved in cancer growth. It is being studied alone or in combination with other treatments in people with locally advanced or metastatic breast cancer. The goal is t…

This study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…

This study follows young women with hormone-sensitive breast cancer who stayed premenopausal or resumed menstruation after chemotherapy. Researchers are investigating whether adding two years of ovarian function suppression to standard tamoxifen therapy can lower the chance of ca…

This trial tests whether a drug called trilaciclib can prevent myelosuppression — a drop in blood cell counts — caused by a type of chemotherapy known as topoisomerase I inhibitor antibody-drug conjugates (ADCs). About 96 cancer patients who are scheduled to receive these ADC dru…

This phase III trial is testing whether a new drug called BL-B01D1, combined with an immunotherapy (PD-1 antibody), works better than standard chemotherapy plus immunotherapy for people with advanced triple-negative breast cancer that has a specific protein (PD-L1). The study inc…

This early-stage trial tests a new drug called SHR-4685 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 170 adults aged 18 to 75 with meas…

This trial investigates whether adding neratinib, a drug that blocks HER2/3/4 proteins, to standard hormone therapy can improve disease control in people with metastatic ER+/HER2- breast cancer that has stopped responding to first-line endocrine therapy. Participants will receive…

This study tests a drug called sacituzumab tirumotecan in 20 people with triple-negative breast cancer that has spread to the brain. The drug is given through a vein twice a month. The main goal is to see if it can shrink brain tumors. This is an early-phase trial, so it focuses …

This phase II trial is testing an experimental drug called SMP-656 in people with HER2-positive breast cancer that has spread or cannot be removed and has worsened after prior treatment with a specific type of antibody-drug conjugate. The study aims to see if SMP-656 can shrink t…

This trial is investigating whether women with node-positive breast cancer whose lymph nodes are cancer-free after chemotherapy can safely receive less extensive radiation. Instead of radiating the entire lymph node region, the study compares standard radiation to a more targeted…

This trial is testing an experimental drug called ML-016, a nanoparticle form of the chemotherapy doxorubicin, in people with advanced solid tumors that have spread to the lungs or liver. The study aims to find the safest dose and see whether the drug can shrink tumors or slow th…

This phase II trial is testing whether a vaccine called STEMVAC can help prevent triple-negative breast cancer from coming back after surgery. The vaccine targets proteins that cancer cells use to grow and spread, aiming to boost the immune system to destroy any remaining tumor c…

This phase 3 trial tests whether a single dose of SRG-514 (ketorolac), given directly into the area where a breast tumor is removed, can help prevent cancer from coming back. The study enrolls adults with stage II-III triple-negative breast cancer who are having breast-conserving…

This trial tests a planned sequence of treatments for people with advanced or metastatic HER2-positive and hormone receptor-positive breast cancer. Participants first receive T-DXd (Enhertu) plus pertuzumab, then switch to a maintenance combination of palbociclib, endocrine thera…

This early-phase trial tests a drug called CAN1012 in 24 people with pre-cancerous breast conditions (DCIS or LCIS). The drug is injected directly into the lesion to activate the immune system. The main goal is to check safety and ensure the treatment doesn't delay necessary surg…

This trial tests an experimental drug called HMPL-A830 in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then testing that dose in more people to see if it can shrink tumors. The goal is to un…

This early-stage trial is testing an experimental oral drug called HW221043 in adults with advanced solid tumors who have no standard treatment options left. The study has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors or slow their gro…

This trial tests a care package called the 'WARNING Pack' for people aged 75 and older with cancer. The pack helps doctors spot early signs of age-related problems and provides a guide for managing them. The goal is to prevent a decline in quality of life and reduce the risk of g…

This study tests whether adding a new oral drug called fulvestaciclib to standard anti-HER2 and hormone therapy can help people with HR+/HER2+ advanced breast cancer live longer without their disease getting worse. Some participants receive the combo after initial chemotherapy, w…

This phase 3 trial tests whether monitoring tumor DNA in the blood (ctDNA) can help doctors switch hormone therapy earlier in people with ER+/HER2- metastatic breast cancer. Participants whose ctDNA levels rise—before any symptoms or scans show progression—are randomly assigned t…

This phase 1 trial tests an experimental drug called TJ037130 in adults with advanced solid tumors, including ovarian, gastric, and endometrial cancers that have spread. The main goal is to check the drug's safety and find the best dose for future studies. Participants receive TJ…

This study tests an experimental oral drug called elraglusib in adults with advanced solid tumors that have spread or are not responding to standard treatments. The trial aims to find the safest dose and evaluate how the body processes the drug, while also looking for early signs…

This study explores whether cancer patients can safely receive proton radiation therapy while sitting upright instead of lying down. The upright system is already FDA-cleared, and the goal is to see if it works reliably for a range of patients. Researchers will track treatment su…

This trial compares how well patients tolerate dalpiciclib versus abemaciclib or ribociclib when each is combined with standard hormone therapy for high-risk HR+/HER2- early breast cancer. About 456 patients who have completed initial local treatment will be randomly assigned to …

This early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…

This pilot trial tests whether adding the drug alisertib to usual care can help people with advanced HR+/HER2+ breast cancer whose disease has become resistant to standard treatments. Researchers want to see if alisertib can block communication between hormone receptors and HER2,…

This early-stage trial tests an experimental therapy called GKL-006Allo, made from donor immune cells (iNKT cells), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the therapy's safety and how the body processes it.…

This study tests whether adding ivermectin, a drug used for parasitic infections, can improve the immune response in people with solid tumors who are already receiving immunotherapy. About 80 adults will take either a moderate or high dose of ivermectin for four weeks alongside t…

This trial is studying a combination of two targeted drugs, patritumab deruxtecan and trastuzumab deruxtecan, for people with a specific type of advanced breast cancer that is hormone receptor positive and has low or ultra-low levels of a protein called HER2. The study aims to fi…

This study investigates whether adding isunakinra, a modified protein that blocks inflammation, can make triple-negative breast cancer more sensitive to standard immunotherapy and chemotherapy. The trial enrolls adults with newly diagnosed, locally advanced triple-negative breast…

This trial tests a new drug called VBC108 in people with advanced solid tumors that have not responded to standard treatments. VBC108 is designed to attach to two specific proteins (CLDN18.2 and CDH17) found on some cancer cells and deliver a toxic payload to kill them. The study…

This study tests an experimental drug called LM-364, given alone or with another cancer drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 90 adults…

This study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…

This study tests a combination of three drugs—tislelizumab, bevacizumab, and capecitabine—in people with advanced solid tumors. The trial focuses on two challenging groups: those whose cancers have stopped responding to immunotherapy and those with tumors that have spread to the …

This early-phase study tests a new drug called KIVU-305 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find a safe dose and see if the…

This trial tests an experimental drug called HSK46256, which blocks a protein called PARP1 that helps repair DNA in cancer cells. The study includes adults with advanced solid tumors who have not responded to standard treatments. Researchers aim to find the safest dose and check …

This trial tests an experimental drug called VBC106 in people with advanced solid tumors that have not responded to standard treatments. VBC106 is designed to target two proteins (FRα and MSLN) found on some cancer cells, delivering a toxic payload directly to the tumor. The stud…

This trial tests an experimental drug called SYH2095, taken as a daily pill, in people with advanced solid tumors that have no effective standard treatment. The drug blocks a protein (KAT6A/B) involved in cancer cell growth. The study aims to find a safe dose and check for early …

This study tests whether adding lovastatin, a common cholesterol-lowering drug, can help the cancer treatment trastuzumab deruxtecan work better in people with HER2-low or ultralow advanced breast cancer. About 60 participants will receive both drugs to see if more tumors shrink …

This study tests whether a combination of three drugs—kumorixilib, capecitabine, and letrozole—given before surgery can slow or shrink tumors in people with HR-positive, HER2-negative breast cancer. Participants take the drugs for six 28-day cycles, then have surgery. The main go…

This phase 2 trial investigates whether tirzepatide, a drug used for weight loss and diabetes, can slow tumor growth in people with early-stage hormone-receptor-positive breast cancer. Participants receive tirzepatide alone, the standard hormone therapy letrozole alone, or both t…

This trial investigates whether surgically removing the primary breast tumor, followed by standard systemic therapy, improves survival compared to systemic therapy alone in women with stage IV breast cancer that has spread only to a single bone site. The study enrolls women aged …

This pilot study tests a device that uses short, high-frequency electrical pulses to shrink or destroy soft tissue tumors in people with metastatic breast cancer. The trial will enroll 20 adults with tumors near the skin that are at least 1 cm but no larger than 5 cm. The main go…

This study tests a new treatment called VG2025, a modified herpes simplex virus designed to infect and kill cancer cells while also boosting the immune system. The trial enrolls adults with advanced solid tumors that have not responded to standard therapies and who have previousl…

This Phase 3 trial compares two forms of the chemotherapy drug utidelone—a capsule taken by mouth versus an injection—both combined with another chemo drug, capecitabine, in people with HER-2 negative advanced breast cancer. The study aims to see if the oral capsule works as well…

This trial provides continued access to three experimental Bicycle therapies—zelenectide pevedotin, nuzefatide pevedotin, and BT7480—for people with advanced solid tumors who are already benefiting from them in another study. Participants continue their same treatment while resea…

This study provides continued access to alpelisib for people who are already benefiting from it in a previous Novartis trial. It focuses on tracking long-term safety, including any side effects, in participants with PIK3CA-related overgrowth spectrum or certain breast cancers. Pa…

This Phase 3 trial tests whether a combination of two drugs, trastuzumab rezetecan and adebrelimab, can prevent breast cancer from returning in people with triple negative breast cancer who still have cancer cells after initial chemotherapy and surgery. The study compares this ne…

This study investigates cryoablation, a procedure that freezes and destroys tumor tissue, for treating the primary breast tumor in women with metastatic breast cancer. The goal is to see if this minimally invasive approach can control the local tumor for 12 months while patients …

This pilot study tests whether adding a device called TheraBionic P1 to standard treatment can help women with metastatic triple negative breast cancer who have already tried two prior treatments. The device delivers low-level radiofrequency electromagnetic fields and is used alo…

This early-phase trial is testing whether two experimental drugs, SCTB41 and SCTB39G, given together every three weeks, are safe and can shrink tumors in adults with advanced solid tumors that have not responded to standard treatments. The study will enroll 112 participants acros…

This phase 3 trial is testing a drug called trastuzumab rezetecan, alone or combined with bevacizumab, in 140 women with advanced triple-negative breast cancer that has a specific immune-suppressed pattern. The goal is to see if the combination can delay cancer growth better than…

This early-phase trial tests an oral drug called Zn-Telomir in 76 adults with advanced or metastatic triple-negative breast cancer that has worsened after prior treatments. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors. It is…

This extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of …

This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…

This early-stage trial is testing a new cell therapy called GK01 in 10 people with advanced solid tumors that have stopped responding to standard treatments. The therapy uses the patient's own immune cells (T cells) that are trained to attack the tumor. The main goal is to check …

This early-stage trial tests LNF2105, a drug designed to target and deliver a toxin to cancer cells that have a protein called Nectin-4 on their surface. It will enroll about 294 adults with advanced solid tumors (such as bladder, breast, or lung cancer) who have run out of stand…

This early-stage trial tests a new approach to CAR-T therapy where a virus is injected directly into the bloodstream to reprogram a patient's own immune cells to attack cancer. It involves 91 adults with advanced solid tumors who have run out of standard options. The main goal is…

The SASHA trial is testing whether a single, high-dose radiation treatment delivered directly to the tumor site over one day is safe and effective for women with early-stage breast cancer. The study will enroll 134 women aged 40-85 who have already had a lumpectomy. Researchers w…

This study tests a risk-based approach to radiation after breast-conserving surgery for early breast cancer. Depending on individual risk, patients receive either whole-breast or partial-breast radiation in fewer, larger doses (hypofractionation). The goal is to maintain cancer c…

This Phase 2 trial tests BL0175, a nano-medicine that delivers cancer-fighting drugs directly into tumors. It enrolls 120 postmenopausal women with HR+/HER2- advanced breast cancer. Researchers compare different doses to find the safest and most effective one for shrinking tumors…

This early-stage trial is testing two experimental drugs, OVV-01 and AK112, in 30 people with advanced solid tumors that have not responded to standard treatments. OVV-01 is given both into a vein and directly into the tumor, while AK112 is given into a vein. The main goals are t…

This early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safe…

This Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.

This phase II trial is testing a three-drug combination given before surgery for people with intermediate-to-high risk HR-positive, HER2-low breast cancer. Participants first take dalpiciclib (a pill) plus an aromatase inhibitor (another pill) for about 4 months, followed by infu…

This study tests a drug called SHR-A1811 in 60 adults with HER2-positive advanced breast cancer who have had up to 2 prior treatments. Researchers want to see if giving the drug in different ways (like injection or infusion) can shrink tumors. The main goal is to measure how many…

This early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …

This study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participa…

This study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…

This study tests whether a new drug, trastuzumab rezetecan, works as well as or better than the current drug trastuzumab deruxtecan for women with advanced HER2-positive breast cancer that has worsened after previous treatment. About 100 women will be randomly assigned to one of …

This study looks at whether a structured support program can help people with early-stage, hormone-positive breast cancer stick to their ribociclib medication (taken with an aromatase inhibitor). About 90 participants will be split into two groups: one gets standard care, the oth…

This study tests whether a new drug, sacituzumab tirumotecan (Sac-TMT), followed by standard chemotherapy (capecitabine), works better than capecitabine alone to keep early-stage, high-risk triple-negative breast cancer from returning. About 420 women without BRCA gene mutations …

This study tests a new drug called FG-B901, a bispecific antibody that targets two immune proteins (PD-L1 and CD40) to activate the immune system against tumors while reducing side effects. It is given alone or with chemotherapy to 264 adults with advanced solid tumors that have …

This phase 2 trial is testing a combination of three drugs—inavolisib, ribociclib, and fulvestrant—in 160 Chinese women with a specific genetic mutation (PIK3CA) in hormone receptor-positive, HER2-negative advanced breast cancer that has stopped responding to endocrine therapy. T…

This early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…

This study tests a combination of two drugs, zongertinib and fulvestrant, in people with advanced breast cancer that is hormone receptor-positive and HER2-negative but has a specific HER2 gene mutation. The goal is to see if the combination shrinks tumors. About 25 adults will ta…

This study tests a new drug (SYS6006) combined with another drug (Enlonstobart) in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and works better than Enlonstobart alone. About 264 adults will tak…

This early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…

This early-phase study tests a new treatment called CAR-DC for people with advanced solid tumors (like lung, liver, or stomach cancer) that have not responded to standard care. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells. …

This early-stage trial tests a new drug called Hemay5087 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrin…

This early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…

This early-phase trial tests a new drug called WSK-IM02 in 9 people with advanced solid tumors that have spread to cause fluid buildup around the lungs or in the belly. The drug is given directly into the chest or abdomen to see if it is safe and can shrink tumors or reduce fluid…

This early-phase trial tests a combination of two drugs, CVL006 and 9MW2821, in 108 adults with advanced solid tumors that have not responded to standard therapy. The goal is to find a safe dose and see if the combination can shrink tumors. The study is not yet recruiting.

This early-stage trial tests a new drug called CS231295 in 42 adults with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking certain proteins that help tumors grow and form blood vessels. The main goals are to check safety, find …

This Phase 2 trial will enroll 100 young women (ages 18-45) with hormone receptor-positive breast cancer who are already on a 3-month GnRH injection for ovarian suppression. Half will switch to a monthly injection, while the other half stays on the 3-month schedule. The study aim…

This phase III trial is for people with HER2-positive stage IV breast cancer that has spread to a limited number of spots (oligometastatic). It tests whether adding surgery and focused radiation to standard drug therapy helps them live longer or delays cancer growth compared to d…

This study tests whether a new biosimilar drug, HLX319, works as well as the approved drug Phesgo for people with HER2-positive early or locally advanced breast cancer. About 258 participants will receive either the biosimilar or the original drug before surgery to compare how th…

This early-stage trial tests a new drug called HF50 in 45 adults with advanced solid tumors that have not responded to standard treatments. HF50 is designed to target HER2 on cancer cells and boost the immune system. The main goals are to check safety, find the right dose, and se…

This study tests whether starting abemaciclib at a lower dose and gradually increasing it can reduce early side effects like diarrhea and fatigue in people with high-risk HR+/HER2- breast cancer. The goal is to help more patients stay on their full treatment plan. About 86 partic…

This early-phase study tests a new drug called IN10028 in 75 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors when used alone or with other cancer drugs. Th…

This study tests a program to help women with ER-positive breast cancer in Rwanda take their daily hormone therapy as prescribed. The program includes education, reminders, and behavioral support. Researchers will measure how well participants stick with their medication and how …

This study tests two experimental drugs (SCTB41 and SCTB39-1) given together, sometimes with standard cancer therapy, in adults with advanced solid tumors that have not responded to prior treatments. The goal is to find safe doses and see if the combination can shrink tumors or s…

This study tests whether adding 4 cycles of the targeted drug trastuzumab rezetecan (T-DXh) can eliminate residual cancer in HER2-positive breast cancer patients who still have disease after standard chemotherapy. About 59 adults will receive the drug before surgery. The main goa…

This early-stage trial tests a new drug (non-cationic peptide-CD47 siRNA) in about 9 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a 'don't eat me' signal on cancer cells, helping the immune system recognize and attack t…

This early-stage trial tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a special antibody that targets two cancer-related proteins, EGFR and cMET, to potentially slow or stop tumor growth. The mai…

This early-phase trial tests a new mRNA-based immunotherapy called PMC2129G12 in 60 adults with advanced solid tumors that have not responded to standard treatments. The therapy is injected directly into tumors to help the body's immune T cells attack cancer cells. The main goals…

This study tests a combination of targeted drugs (trastuzumab and pertuzumab) plus a low-dose chemotherapy (vinorelbine) given before surgery to elderly patients (70+) with HER2-positive breast cancer. The goal is to see if this approach can completely eliminate cancer cells in t…

This study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…

This trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…

This early-phase trial tests a new drug called SYS6051 in 114 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive the drug by IV every three weeks.

This early-phase study tests a new mRNA medicine (NCP-IL-22BP mRNA) in 9 people with advanced solid tumors that have not responded to standard treatments. The medicine is injected directly into tumors to help the body fight cancer. The main goal is to check safety and find the ri…

This Phase 2 trial tests a new combination of drugs—paclitaxel polymer micelles, trastuzumab, pertuzumab, and adebelimab—against the standard taxane-based regimen for people with advanced HER2-positive breast cancer. About 140 participants will be randomly assigned to one of the …

This study tests a new combination of drugs (PLD, cyclophosphamide, trastuzumab, and pertuzumab) for people with HER2-positive early breast cancer who still have cancer after initial treatment. The goal is to see if this combo can increase the rate of complete remission before su…

This early-stage trial tests a new drug called AK150 in about 96 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will also look for signs that the drug shrinks tumors.

This study looks at envafolimab, a cancer drug given as a quick shot under the skin instead of a long IV drip. It is for adults with advanced solid tumors who have not responded to standard treatments. The goal is to see how well it controls tumors and what side effects occur in …

This phase 3 trial compares a new drug called 9MW2821 to standard chemotherapy in 356 people with advanced triple-negative breast cancer who have already received certain prior treatments. The main goal is to see if the new drug helps people live longer. Participants will receive…

This early-phase trial tests an experimental drug called FXB0871 in about 138 adults with advanced solid tumors, including non-small cell lung cancer and liver cancer, that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and se…

This study tests whether combining brain radiation with a targeted drug (dalpiciclib) and hormone therapy can help control breast cancer that has spread to the brain in people with HR-positive/HER2-negative disease. About 46 participants will receive the combination and be follow…

This study tests a new drug called AK138D1, given alone or with another drug (ivonescimab), in people with advanced breast cancer. The goal is to see if the treatment is safe and can shrink tumors. About 286 adults aged 18 to 75 will take part. This is an early-stage trial, so th…

This early-phase trial tests a new combination treatment for people with advanced breast cancer that has not responded to standard therapies. The treatment uses specially engineered immune cells (TRICK-NK) plus a targeted drug called T-Dxd. The study aims to find the safest dose …

This study tests whether a pharmacist-led program — including medication review, counseling, and follow-up — can help adult cancer outpatients take their medications correctly and avoid errors. One hundred participants will be split into two groups: one receives standard care plu…

This study looks at how well a drug called inavolisib works in real-world settings for people with a certain type of advanced breast cancer (HR-positive, HER2-negative, with a PIK3CA mutation). About 100 participants will take inavolisib along with hormone therapy, sometimes with…

This phase 2 study tests whether a new drug called JSKN003 works better than the current standard therapy for people with HER2-positive breast cancer that has returned or spread. About 60 adults who have not had prior treatment for advanced disease will receive either JSKN003 or …

This study tests a new combination of drugs (zanidatamab, tucatinib, and chemotherapy) in people with advanced HER2-positive breast cancer that cannot be removed by surgery or has spread. The goal is to find the safest dose and see if the treatment shrinks tumors. About 24 adults…

This study tests a new type of breast-conserving surgery that uses a small camera inserted through a hidden armpit incision to remove tumors, compared to the standard open approach. About 1,366 women with early-stage breast cancer will be randomly assigned to one of the two surge…

This phase 2 trial tests whether adding a targeted drug (axatilimab) and radiation to the immunotherapy pembrolizumab can help shrink tumors in people with metastatic triple-negative breast cancer who have already tried immunotherapy. About 34 participants will receive all three …

This study tests whether a special PET scan (HER2-PET) can help doctors personalize treatment for early-stage HER2-positive breast cancer. After two cycles of standard therapy, the scan results will determine if patients need stronger or milder treatment. The goal is to improve t…

This study tests a personalized approach for people with HER2-positive breast cancer. After two cycles of standard therapy, those whose tumors shrink less than 40% will switch to a new drug combination (SHR-A1811 plus pertuzumab) for four more cycles before surgery. The goal is t…

This early-stage trial tests crotoxin, a protein from rattlesnake venom, given intravenously to 24 adults with advanced solid tumors that have not responded to standard therapy. The main goal is to see if a slow dose increase can make the drug safer and better tolerated. Research…

This study tests whether a drug called edaravone dexborneol can help people who have a stroke while also having active cancer. The drug is given by IV twice a day for 10-14 days. Researchers will check if it improves recovery and is safe. About 144 adults aged 18-80 will take par…

This study compares two chemotherapy drugs—gemcitabine and paclitaxel—in Black Caribbean women with metastatic triple-negative breast cancer. The goal is to see if gemcitabine, usually used later, works better as a first treatment. 750 women from Jamaica, Trinidad, and Barbados w…

This study tests a new drug called ALK-N001 in 190 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every 2 or 3 weeks. Researchers will check if it shrinks tumors, how safe it is, and how the body processes it. The goal is…

This study is for people with advanced triple negative breast cancer, a type that is harder to treat. It tests a new oral liquid drug called BLEX 404 given with the chemotherapy drug Docetaxel. The goal is to find a safe dose and see if the combination helps shrink tumors. About …

This study looks at whether extra education and counseling helps women with HR+/HER2- early breast cancer take their prescribed medication, abemaciclib, more consistently. About 257 women will either receive standard care or additional coaching. The main goal is to see if coachin…

This study tests a new drug called KHN922 in people with advanced solid tumors that have not responded to standard treatments. KHN922 is an antibody-drug conjugate designed to target HER3 proteins on cancer cells and deliver two anti-cancer drugs directly to them. The trial will …

This trial is for people with ER-positive, HER2-negative advanced breast cancer whose disease has started to grow in a few spots while on hormone therapy and a CDK4/6 inhibitor. It tests whether adding targeted radiation (SABR) to those spots allows patients to stay on their curr…

This study tests a new drug, QLC5513, alone or with another drug (QL1706) in 60 women with advanced triple-negative breast cancer that has worsened after at least one prior treatment. The goal is to see if these drugs can shrink tumors or slow the cancer's growth. Participants wi…

This early-phase trial is testing a new chemotherapy drug called RP-001 in 66 adults with advanced solid tumors, including colorectal and pancreatic cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is an open-label study, …

This study tests a new drug, JCXH-211, injected directly into tumors along with an anti-PD-1 antibody given through an IV. It is for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the combination is safe and tolerable …

This study tests whether adding the immunotherapy drug camrelizumab to chemotherapy and radiation before surgery can eliminate all signs of early-stage triple-negative breast cancer. About 43 women with newly diagnosed, untreated disease will receive the combination for 12 weeks,…

This Phase 2 trial tests a new drug called HLX43, which is designed to seek out and destroy cancer cells in people with advanced triple-negative breast cancer (TNBC). The study will test HLX43 alone or combined with other immune-boosting drugs. About 180 adults with TNBC that has…

This early-stage trial tests a new cell therapy called GK01 in 15 people with advanced solid tumors that have not responded to standard treatments. GK01 uses a patient's own immune cells, trained to attack their cancer. The main goal is to find a safe dose and check for side effe…

This study will follow 500 people with HER2-positive advanced breast cancer who are starting treatment with pyrotinib, a daily oral targeted therapy. Researchers want to see how well the drug controls the cancer and what side effects occur in everyday medical practice, not just i…

This early-stage trial tests a new biologic drug, SIG001, in 66 people with advanced solid tumors. The main goals are to check safety, find the right dose, and see how the drug behaves in the body. Participants receive SIG001 intravenously every two weeks and are monitored for si…

This study tests whether adding the immunotherapy drug pembrolizumab to usual post-surgery treatment can help prevent breast cancer from returning in people with early-stage triple-negative breast cancer who still had cancer after initial chemo and pembrolizumab. About 1,000 adul…

This early-stage trial tests a new oral drug called HLX97 in 138 people with advanced solid tumors (breast, prostate, or lung cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can slow tumor g…

This study tests whether taking vitamin C and coenzyme Q10 can prevent kidney damage in cancer patients receiving cisplatin chemotherapy. About 75 adults with various cancers who have not had chemo before will take these supplements alongside their treatment. The goal is to see i…

This early-phase study tests a new drug called JSKN016HC in about 42 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants must be in fairly …

This phase 2 trial will test a combination of two drugs—serplulimab (an immunotherapy) and SHR-A1811 (a targeted chemotherapy)—given before surgery to women with early-stage triple-negative breast cancer. The main goal is to see how many patients have no cancer left at the time o…

This study tests an experimental oral drug, BPI-572270, in 120 adults with advanced solid tumors (lung, colorectal, or pancreatic cancer) that have specific RAS gene mutations. The trial has two phases: first to find a safe dose and check for side effects, then to see if the drug…

This phase II trial tests whether combining multi-mode thermal therapy (heat treatment) with immunotherapy drugs can help people with HER2-negative breast cancer that has spread to the liver. The study will enroll 30 participants who have already tried at least one prior treatmen…

This study looks at whether adding pyrotinib to two standard drugs (trastuzumab and pertuzumab) can help control HER2-positive advanced breast cancer longer. About 42 adults with advanced disease will receive this combination as maintenance therapy after initial treatment. The ma…

This phase 2 trial tests a new drug called HLX43 in 60 people with a common type of advanced breast cancer (HR+ HER2-) that has worsened despite standard hormone therapy. The drug is an antibody-drug conjugate that targets PD-L1 to deliver chemotherapy directly to cancer cells. T…

This early-phase study tests a new drug called QLS5308 in about 192 adults with advanced solid tumors that have spread and cannot be removed by surgery or radiation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants m…

This phase 2 trial tests whether injecting the anesthetic levobupivacaine around the tumor and nearby nerves during breast cancer surgery can reduce the risk of the cancer returning. The study will include 760 women with triple-negative breast cancer who have had chemotherapy and…

This early-phase trial tests a new radioactive drug, 177Lu-INN805, in 10 people with advanced solid tumors (like head & neck, lung, breast, or sarcoma) that haven't responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers wi…

This study tests an experimental drug called QLS5132, given with other cancer treatments, for people with advanced solid tumors like stomach, lung, endometrial, and ovarian cancers. The goal is to find safe doses and see if the combination shrinks tumors. About 626 participants w…

This study tests a new approach for women with a common type of early breast cancer (HR+/HER2-). Instead of standard chemotherapy before surgery, some participants will receive a combination of hormone therapy and a targeted drug (abemaciclib) based on their tumor's gene test res…

This early-phase trial tests whether combining the targeted drug trastuzumab deruxtecan (T-DXd) with precise radiation (SRS) is safe for people with HER2-positive breast cancer that has spread to the brain. Up to 20 participants will receive the drug by IV every three weeks along…

This early-phase trial will test the safety and tolerability of combining a CDK4/6 inhibitor (abemaciclib) with radiation therapy after surgery in 30 women with HR+/HER2- high-risk breast cancer. The study aims to find the highest safe dose of the drug when used alongside radiati…

This phase 2 trial tests a combination of two drugs—entinostat and oral paclitaxel—in 50 people with HR-positive, HER2-negative advanced breast cancer who have already tried 2 to 4 prior treatments. The goal is to see if the combo can delay cancer growth. Participants take both d…

This study tests a combination of two drugs, inavolisib and eribulin, in people with advanced triple-negative breast cancer that has a PIK3CA mutation and has not responded to at least one prior treatment. The goal is to see if the combination shrinks tumors and is safe. About 26…

This early-stage study tests a new drug called T320 in 150 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive T320 every two wee…

This early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…

This early-phase trial tests an experimental drug called ITC-6146RO in about 102 adults with advanced or metastatic cancers (like prostate, lung, or breast cancer) that have not improved with standard treatments. The study has two parts: first, finding a safe dose, then checking …

This study looks at whether a combination of ribociclib (a targeted drug) and hormone therapy can be as effective as chemotherapy followed by the same combo for people with a common type of early breast cancer (HR+/HER2-). Only patients whose blood tests show no signs of cancer D…

This study tests whether taking letrozole, a hormone therapy pill, for one year before surgery can shrink tumors and clear cancer from lymph nodes in postmenopausal women with early-stage, hormone-sensitive breast cancer. All 126 participants will take letrozole daily and then ha…

This phase 2 trial tests whether a new drug, trastuzumab-rezetecan, works as well as the established drug T-DXd in shrinking HER2-positive breast tumors before surgery. About 68 women with early or locally advanced breast cancer will receive one of the two drugs for 8 cycles, the…

This study tests whether a three-drug combination can help people with triple-negative breast cancer whose tumors stopped responding to immunotherapy. About 46 women will receive cromolyn, TQB2102, and panpulimab to see if tumors shrink or stop growing. The goal is to control the…

This Phase 2 trial tests whether adding the experimental drug QL1706 to standard platinum chemotherapy helps people with advanced triple negative breast cancer live longer without their disease getting worse. About 78 adults who have already had one or two prior treatments will b…

This study tests whether taking two drugs (imlunestrant and abemaciclib) before surgery can shrink tumors in people with a common type of breast cancer (ER+/HER2-). About 189 women aged 18-75 with early-stage breast cancer will join. The treatment is guided by a marker called Ki6…

This study compares a new drug, SHR-A1811, with a standard combination therapy (pyrotinib plus capecitabine) in 100 adults with advanced HER2-positive breast cancer that did not respond to the first-line treatment trastuzumab. The goal is to see which approach better delays cance…

This early-phase trial tests a new type of cell therapy called CAR-Macrophages in 20 adults with advanced solid tumors. The immune cells are modified to target specific markers on cancer cells (HER2, PSMA, FAP) and are given by IV. The main goals are to check safety, find the bes…

This study tests whether taking the oral drug everolimus after standard chemotherapy can help prevent breast cancer from coming back in people with a specific subtype of triple-negative breast cancer called LAR. The trial will enroll 904 women who have had surgery for early-stage…

This study is for people with HER2-negative breast cancer whose tumors did not shrink after initial chemotherapy. Researchers are testing whether adding an immunotherapy drug (toripalimab) and targeted radiation before and after surgery can improve outcomes. About 110 participant…

This early study tests a new treatment called CAT-101, which uses a patient's own immune cells (dendritic cells) loaded with a cancer protein (mKRAS) to help the body fight tumors. It is for people with advanced pancreatic cancer or other solid tumors that have a specific KRAS mu…

This Phase 3 trial tests whether adding the experimental drug NTQ1062 to standard hormone therapy (fulvestrant) can slow or stop the growth of advanced HR+/HER2- breast cancer in people whose cancer has returned or worsened after hormone therapy. The study includes 210 adults wit…

This early-phase study tests a new drug called JSKN027 in 250 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. The study focuses on colorectal, lun…

This early study tests a new radioactive antibody called NTH-2403 in 16 people with advanced colorectal, head and neck, lung, or triple-negative breast cancers. The antibody targets a protein found on cancer cells and their supporting cells, allowing doctors to see tumors on scan…

This trial tests whether a new imaging agent called INR 202, used with a PET/CT scan, can detect more tumors than the standard FDG-PET/CT in people with advanced solid tumors. Thirty adults with advanced cancer will receive both scans to compare how many lesions each method finds…

This early-phase study tests a new radioactive imaging probe that targets a protein called FAP, found on many solid tumors. The probe is used with PET or SPECT scans to see if it can better locate tumors and determine if they have spread, compared to standard FDG-PET imaging. The…

This early-phase study tests a new imaging agent that targets a protein called TROP2, found on many cancer cells. About 40 adults with metastatic bladder, breast, or lung cancer will receive the agent to see where it goes in the body. The goal is to see if this tracer can help do…

This early-phase study tests a new radioactive tracer called [68Ga]Ga-FFD for PET imaging in healthy volunteers and people with solid tumors. The goal is to see if it is safe, where it goes in the body, and how well it spots tumors compared to standard imaging. Researchers will a…

This study will develop and test an AI model that combines MRI, ultrasound, digital pathology, and patient data to predict how well breast cancer responds to neoadjuvant therapy. Researchers will analyze data from 1,800 participants across multiple centers. The goal is to help do…

This early-stage study will test a new radioactive tracer called [89Zr]DFO-YS5 in 40 people with nerve sheath tumors, bladder cancer, or other advanced solid tumors. The tracer is designed to bind to cancer cells and show up on PET scans, potentially making tumors easier to see. …

This study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and ha…

This study will test if artificial intelligence can create clear breast MRI images without using contrast dye. Researchers will use a special type of MRI scan (diffusion-weighted imaging) to generate synthetic images that might help diagnose breast cancer. If successful, this cou…

This study tests whether a special ultrasound technique (super-resolution imaging) can predict if breast cancer will completely respond to chemotherapy after just one cycle. Researchers will enroll 150 women with invasive breast cancer scheduled for chemotherapy. The goal is to s…

This study tests an artificial intelligence (AI) system that analyzes breast images (digital breast tomosynthesis) to help doctors diagnose breast cancer more accurately. Researchers will train the AI on thousands of images from 5000 women to detect tumors, tell benign from malig…

This study tests a new radioactive tracer called 68Ga-MY for PET scans. It targets a protein (5T4) found on many cancer cells but rarely on healthy cells. About 20 people with lung or breast cancer will get both a standard FDG scan and a 68Ga-MY scan. Researchers will compare the…

This study will compare two types of scans—PET/CT and CT—to see which is better at finding distant spread of breast cancer. About 97 patients with advanced breast cancer will receive both scans within a few weeks. The goal is to improve early staging and guide treatment to improv…

This study tests whether a new MRI contrast agent, gadopiclenol, can detect brain metastases earlier than standard methods in 180 patients with advanced lung, breast, or skin cancer. Participants will receive screening brain MRIs to compare diagnosis timing and accuracy. The goal…

This study will test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can accurately measure the size of breast tumors in people with ductal carcinoma in situ (DCIS). Twelve participants will receive both a standard MRI and an FCI scan before surgery. The results…

This study tests whether regular blood tests (ctDNA) can find triple-negative breast cancer recurrence earlier than standard follow-up. Thirty patients who had surgery for stage II or III TNBC will be randomly assigned to either standard care or standard care plus ctDNA testing e…

This study tests a new radioactive tracer called 68Ga-DOTA-BLP for PET scans to see PD-L1 levels in tumors. PD-L1 helps cancer hide from the immune system, and knowing its levels can guide immunotherapy. The study will include 50 adults with confirmed cancer and suspicious spots …

This study tests a new PET imaging agent, 68Ga-cPP-BCH, to detect PD-L1 protein levels in tumors of people with lung cancer, melanoma, or other solid tumors. The goal is to see if this scan can identify who might benefit from anti-PD-1/PD-L1 immunotherapy without needing a tissue…

This study tests a new radioactive imaging agent called 68Ga-SFB6-ZN01, which is designed to attach to a protein found on many cancer cells. 98 adults with confirmed or suspected cancer will receive a single injection of the agent and then have a PET/CT scan. The goal is to see i…

This phase 2 trial is testing an experimental drug called SIR2501 in adults with solid tumors who are about to receive paclitaxel-based chemotherapy. The goal is to see if SIR2501 is safe, tolerable, and might reduce the development of chemotherapy-induced peripheral neuropathy—a…

This trial tests whether adding auricular acupressure—using small seed patches on specific ear points—to standard antiemetic medication can better prevent nausea and vomiting in people receiving highly emetogenic chemotherapy. About 332 patients with solid tumors will be randomly…

This study will test different methods to prevent infections and other problems from central lines (tubes placed in large veins) in 2,500 patients. It compares special antimicrobial caps and a skin anchor device against standard care. The goal is to find the best ways to keep pat…

This study tests whether providing online webinars, digital tools, and a logbook can help adults at high risk for breast cancer become more physically active. Participants (200 women aged 30-69) will either receive the full motivation package or just standard activity recommendat…

This study will test whether a 12-week program of supervised aerobic and strength exercises can prevent heart problems in 60 adults undergoing chemotherapy for cancer. Participants will be split into an exercise group and a usual-care group. Researchers will measure heart functio…

This study tests whether electroacupuncture (acupuncture with mild electrical pulses) combined with tiny thumbtack needles can prevent peripheral neuropathy—numbness, tingling, or pain—caused by chemotherapy in people with advanced cancer. The trial enrolls adults with stage IV b…

This study tests whether low doses of two hormone-blocking drugs, exemestane and tamoxifen, can help prevent breast cancer in postmenopausal women at high risk. About 140 women will take one of the two drugs for a year, and researchers will measure side effects and quality of lif…

This study tests a surgical technique done at the same time as breast cancer lymph node removal to prevent arm lymphedema (chronic swelling). The procedure uses a small flap of tissue from the side of the chest to rebuild the armpit area and support fluid drainage. One hundred hi…

This study aims to create and test a virtual group program for young adults (ages 18-39) who have had cancer and are experiencing post-traumatic stress symptoms. The program will be developed with expert feedback and then tested with 80 survivors to see if it is feasible and help…

This trial tests whether cosmeceutical moisturizers can ease skin dryness in people with cancer who experience skin side effects from treatments like chemotherapy or immunotherapy. Participants apply the moisturizers daily for 2-4 weeks and report changes in dryness severity. The…

This pilot trial tests a program called FamilyStrong, designed to help family caregivers of people with advanced cancer manage their own distress. Caregivers receive monthly phone calls from a trained lay navigator who screens for stress, identifies their biggest concerns, and of…

This pilot study will give 20 early-stage cancer patients a preloaded cash card with $1,000 each month. The goal is to see if this simple cash support can prevent financial hardship, like debt or missed rent, and improve treatment outcomes. Researchers will measure how many peopl…

This study tests a 6-session telehealth program called STRIDE, which uses cognitive behavioral therapy to help women with hormone-positive breast cancer manage side effects from adjuvant endocrine therapy. Participants will be randomly assigned to either the STRIDE program or usu…

This study compares standard palliative radiotherapy (24 Gray in 3 sessions) with a higher dose (27 Gray in 3 sessions) for people with large metastatic tumors. The goal is to see if the higher dose improves tumor control without more side effects. About 20 adults with solid tumo…

This study tests a virtual group lifestyle program for women with metastatic breast cancer. The goal is to see if more support helps them stick with healthy habits like diet and exercise. One hundred women will take part, and researchers will track safety and how well they follow…

This phase II trial tests whether low-dose psilocybin, a compound from magic mushrooms, combined with psychotherapy is safe and effective for easing chronic pain in cancer patients who already take opioids. Twenty adults with active cancer and moderate to severe pain will receive…

Many cancer patients feel anxious before radiotherapy, partly due to unfamiliar equipment and procedures. This trial tests whether adding a simulation-based education session — a virtual preview of the treatment environment — before standard education can reduce that anxiety and …

This study is testing a family-centered program called SHINE, designed to support teenagers aged 10 to 17 who have a parent diagnosed with cancer. The program includes about four sessions over eight weeks, focusing on cancer education, family communication, coping skills, and emo…

This study tests a nurse-delivered patient navigation program for women with HER2+ metastatic breast cancer who are taking a specific combination of drugs. The program provides education, symptom management tips, and coping strategies over about 12 weeks. Researchers want to see …

This trial tests whether a type of talk therapy called Acceptance and Commitment Therapy (ACT) can help cancer survivors and their spouses cope with the fear that cancer might return. It compares ACT to a more traditional therapy, Cognitive Behavioural Therapy (CBT), in a two-arm…

This trial tests whether regular text-message check-ins can help advanced cancer patients get palliative care support earlier. Patients receive a text every two weeks asking them to rate their symptoms online. If any symptoms are concerning, a coordinator calls to assess and mana…

This pilot trial tests whether a chatbot powered by large language models can help adolescent and young adult cancer survivors address reproductive concerns. Participants will be randomly assigned to use the chatbot or read an electronic brochure with similar information. The stu…

This trial tests whether a single, two-hour online class called Empowered Relief can help American Indian adults with cancer-related pain. Participants learn three pain relief skills, create a personal plan, and get access to a free audio app for daily practice. The study aims to…

This pilot study tests whether a group telehealth session led by a palliative care pharmacist can help cancer patients better understand and manage their opioid pain medications. Many patients struggle with side effects, complex dosing, and fear of addiction, which can lead to un…

This trial tests whether sending AI-generated summaries of a patient's serious illness conversations to their care team at hospital admission can improve care. The summaries, created by a large language model, highlight the patient's goals and preferences. The study enrolls adult…

This trial tests whether a communication and care coordinator (CCC) can improve serious illness conversations and quality of life for adults with advanced or high-risk cancer. Participants in the intervention group will have six structured sessions over three months to discuss th…

This study tests a program that pairs veterans with advanced cancer with a lay health worker who helps them discuss their goals and preferences for care with their doctors. The goal is to increase the number of veterans who have these important conversations and document their wi…

This trial tests whether a guided digital program delivered through a mobile app can reduce anxiety and depression in young adults (ages 18–40) who have fertility-related distress after a cancer diagnosis. Participants use the app to complete four modules covering coping skills, …

This trial compares two simple treatments—sucking on ice chips or using a lidocaine spray—to see which better prevents or reduces painful mouth sores caused by chemotherapy. About 60 adults with cancer who are about to receive chemotherapy will be randomly assigned to one of the …

This pilot trial tests whether a program of virtual ukulele lessons, called STRUM, can help teenagers preserve cognitive function and emotional resilience while undergoing radiation therapy for cancer. The study enrolls adolescents aged 12 to 17 who are receiving initial radiatio…

This study tests whether a traditional Chinese medicine patch placed on the belly button (Shenque acupoint) can reduce fatigue in cancer patients about to start radiotherapy. Eighty adults with cancer-related fatigue will receive either the real herbal patch or a sham patch daily…

This pilot study tests a financial psycho-oncology program for cancer patients facing financial hardship. Participants attend six one-hour sessions over three months that combine emotional support with practical financial education. The study aims to see if the program is feasibl…

This trial investigates whether daily aromatherapy foot baths with lavender essential oil can help cancer patients manage pain, sleep quality, and fatigue. Over five days, one group receives a 20-minute foot bath with lavender oil, while a control group receives routine care only…

This trial tests an AI-powered avatar called ELISA that helps cancer patients learn about their treatment. Patients starting a new cancer therapy often struggle to remember complex information. The avatar provides personalized answers based on approved content. The study compares…

This study tests whether an AI-assisted expressive writing program can reduce anxiety, emotional distress, and improve quality of life in adults receiving chemotherapy for any type of cancer. Participants are randomly assigned to either use the AI writing tool alongside their usu…

This study is testing a smartphone app called I-STAMP that helps people with advanced cancer keep track of their pain and medications. About 73 participants will use the app and rate how easy it is to use and how helpful it is. The goal is to see if the app can make managing canc…

This study tests whether taking a high dose of whey protein after each workout helps breast cancer survivors gain more muscle and lose more fat compared to exercise alone. Participants are women aged 20 to 89 who have completed treatment for breast cancer and are prescribed exerc…

This study tests whether a combination of two drugs, fosrolapitant and palonosetron, can prevent nausea and vomiting caused by antibody-drug conjugates (ADCs) in cancer patients. Participants are adults with malignant tumors who have never received ADCs before and are about to st…

This study will test whether a mobile app called RestoreMe can help cancer patients get personalized nutrition and activity advice. Researchers plan to enroll 150 adults who are about to start, are currently receiving, or have completed cancer treatment. Participants will use the…

This pilot study tests whether adding a specialized radiation technique called Lattice Radiation Therapy (LRT) to standard palliative radiation can safely shrink large tumors (at least 4.5 cm) in adults. The study will enroll 25 people with various cancers who are already schedul…

This study tests if eating only within an 8-hour window each day (time-restricted eating) can reduce treatment side effects and improve quality of life for people with solid tumors starting adjuvant therapy after surgery. Fifty adults will be randomly assigned to follow this eati…

This study will test a comfort menu and cart for older adults (60+) receiving cancer treatment at a hospital in Brazil. The cart offers items like blankets, pillows, and hygiene kits to improve comfort. Researchers will compare patient and staff experiences before and after the c…

This study tests whether a dietary supplement called Redsenol-1 Plus can safely reduce fatigue in adults who have had cancer treatment. 72 participants will take either the supplement or a placebo for 12 weeks. The main goal is to see if fatigue levels improve, as measured by a s…

This study tests a simple screening tool to identify cancer patients struggling with medical costs. Those who screen positive will be connected to financial counseling and resources at their hospital. The goal is to make it easier for patients to afford their care and reduce fina…

This study tests whether keeping older patients (65+) at a slightly higher body temperature (36.8°C) during major cancer surgery can reduce the risk of delayed neurocognitive recovery—a kind of short-term confusion or memory decline that can happen after surgery. About 1,500 part…

This study tests whether a cannabis gummy can improve sleep and quality of life in 50 cancer patients who have trouble sleeping. Participants will either take the gummy or receive usual care for 5 weeks. The goal is to see if the gummy is safe and helps with sleep, while also che…

This study tests whether a non-invasive technique called transcutaneous electrical acupoint stimulation (TEAS) can prevent or treat sleep problems after cancer surgery. TEAS uses mild electrical pulses on specific points on the skin, based on acupuncture, without needles. The tri…

This study looks at whether adding the drug bupropion (Wellbutrin) to standard hormone therapy can help women with early-stage breast cancer who have lost interest in sex. About 100 women will be randomly assigned to receive either their usual hormone therapy alone or with buprop…

This study will test a structured early rehabilitation program for women who have had breast cancer surgery. The program includes education, gentle exercises starting the day after surgery, and home-based workouts with monitoring. Researchers want to see if it is safe and helps w…

This study tests whether sophrology, a relaxation technique using gentle movements, breathing, and positive visualization, can reduce anxiety in cancer patients undergoing radiation therapy. Fifty-four adults with various cancers will be offered sophrology sessions during their t…

This study tests a group therapy program called LiveWell mBC for women with metastatic breast cancer who are feeling distressed. The program uses adapted Dialectical Behavioral Therapy (DBT) skills to help manage emotions and uncertainty. 48 women will be randomly assigned to eit…

This study tests whether a supervised strength training program can improve quality of life, physical function, and mental health in children with cancer. Twenty participants under 18 who are currently on treatment or dealing with after-effects will do two 50-minute sessions per …

This study tests whether learning progressive muscle relaxation and deep breathing exercises can improve sleep for cancer patients receiving chemotherapy. About 40 adults aged 40-60 with poor sleep will be split into two groups: one gets relaxation training plus usual care, the o…

This study tests whether a 6-week dance-based exercise program can reduce nerve pain and improve quality of life in cancer patients who have nerve damage from chemotherapy. About 76 adults with solid tumors will either join the dance program or receive usual care. The goal is to …

This study tests a spiritual health program called PATH for cancer patients struggling with feelings of disconnection, loss of meaning, or existential distress. Twenty adults with any stage of cancer will attend six workshops combining role-playing, psychology, and dignity therap…

This study tests whether a 14-week personalized exercise program can improve mobility, strength, and quality of life in frail adults aged 65 and older with cancer who have recently been hospitalized. One hundred participants will either follow the adapted physical activity progra…

This study tests whether live, online group strength training can help older cancer survivors (age 65+) who have trouble with daily activities. 150 participants will be split into three groups: immediate strength training, delayed strength training, or stretching. The goal is to …

This study tests whether walking with a robot dog can improve sleep, reduce fatigue, and enhance quality of life in children aged 2-7 who are undergoing cancer treatment. Forty children will be randomly assigned to either robot-dog-assisted walks or usual care. The goal is to see…

This study tests whether a gentle electrical stimulation on the ear (called taVNS) can reduce joint and muscle pain caused by aromatase inhibitors, a common breast cancer treatment. 216 women with hormone-positive breast cancer will receive either real or sham stimulation daily f…

This study tests a new drug called INB301 in people with cancer who are losing weight and muscle (cancer cachexia). The goal is to see if it is safe and can help patients gain or maintain weight. About 146 adults with solid tumors like lung, pancreatic, or colorectal cancer will …

This study tests whether a specially designed AI chatbot can lower anxiety and trauma-related distress in adults recently diagnosed with cancer. Participants will use the chatbot for 12 weeks and complete surveys about their feelings and needs. The goal is to see if this digital …

This Phase 3 trial tests whether electroacupuncture—thin needles with mild electric pulses—can ease cognitive problems like memory loss and trouble focusing in cancer survivors. 168 participants will be assigned to real electroacupuncture, sham (fake) acupuncture, or a waitlist. …

This study tests whether training doctors in shared decision-making and giving patients educational materials improves treatment conversations for HER2-negative metastatic breast cancer. 120 patients starting first-line therapy will be randomly assigned to receive the program or …

This study tests whether THC (with or without CBD) can improve sleep in people with solid organ cancer who have insomnia. About 69 participants will receive either THC, a THC/CBD mix, or a placebo as a liquid under the tongue. The goal is to see if these cannabis-based compounds …

This study tests whether a 6-week gardening and nutrition program can improve quality of life for cancer survivors. Fifteen participants will attend weekly group sessions with gardening, cooking demos, and mindfulness. The main goal is to see if the program is practical and liked…

This pilot study tests whether freeze-dried miracle fruit (MiraBurst) can improve taste changes in people with solid tumors undergoing cancer treatment. About 45 adults will take one mini-square before each meal for 90 days. The goal is to see if this simple supplement can ease a…

This study tests a group-based program for people with cancer that focuses on managing energy, doing meaningful activities, and improving quality of life. About 30 adults with cancer will take part in workshops and hands-on sessions in a community setting. The goal is to see if t…

This study tests whether silkworm pupa tablets can improve nutrition and reduce muscle loss (sarcopenia) in people who have completed cancer treatment. 480 participants will receive either the tablets or a placebo for 3 months. The main goal is to see if muscle strength and mass …

This study tests whether a low-level laser applied to specific points on the ear can improve sleep in women with breast cancer who have insomnia. Seventy participants will receive either real or sham laser acupuncture twice a week for five weeks. Sleep quality, fatigue, and mood …

This study tests whether a smartphone app called the Cancer Exercise app (CEA) can help cancer survivors become more physically active. About 750 adults who have finished cancer treatment will either use the app for 12 weeks or receive usual care. The goal is to see if the app bo…

This study tests whether a single early meeting with a psycho-oncology counselor can reduce anxiety and depression and improve quality of life in people recently diagnosed with cancer. About 148 patients will be randomly assigned to either receive this counseling plus standard ca…

This study tests a new surgical approach for women with early breast cancer who need a nipple-sparing mastectomy. If cancer is found in the nipple during surgery, doctors will remove the nipple but try to save the pigmented skin around it (the areola) and rebuild a new nipple rig…

This study tests a new drug called PDC-1421 to see if it is safe and helps with depression in people who have cancer. About 12 adults with mild to severe depression and stage I-III cancer will take the drug for up to 5 weeks. Doctors will check mood changes using a standard depre…

This study looks at whether adding psychosocial support to standard chemotherapy helps breast cancer patients feel better and respond better to treatment. About 160 Palestinian women with early-stage breast cancer will take part. Half will get usual care, and half will also recei…

This phase 2 trial tests JAK inhibitors (upadacitinib or tofacitinib) in 35 adults with solid tumors who have severe skin rashes from immunotherapy that didn't improve with steroids. The goal is to see if these pills can quickly relieve the rash and itching while allowing patient…

This study tests a special scanner that lets surgeons check, in real time during breast cancer surgery, whether all cancer has been removed. The goal is to reduce the need for a second operation. About 228 women with certain high-risk breast cancer types will take part. The scann…

This study compares two ways of giving a large-volume subcutaneous injection of targeted therapy (pertuzumab and trastuzumab) to 40 women with HER2-positive breast cancer. Each patient will receive one injection by a nurse using a stopwatch to mimic a steady speed, and another in…

This study explores whether equicoaching—a type of coaching with horses—can help young adults (ages 15-25) who finished cancer treatment feel more confident and reconnect with others. Ten participants will take part in the program and share their experiences through interviews an…

This study tests whether a supervised exercise program combining resistance training and walking can improve physical function, fitness, and quality of life in women with stage IV breast cancer. 78 women currently on medical treatment will be randomly assigned to either the exerc…

This study tests whether a digital platform called Beacon can help doctors better manage symptoms in people with advanced cancer. About 40 patients will wear smartwatches and answer questions about how they feel. The platform combines this data to give doctors a clearer picture o…

This study tests an educational program called SHARE-MC designed to help women with metastatic breast cancer address sexual health issues. About 96 women will take part in group video sessions or receive an informational booklet. The goal is to see if the program improves sexual …

This study tests whether personalized cooking and food guidance can help slow muscle loss in people with advanced cancer who are on chemotherapy. About 200 adults will be split into two groups: one gets standard nutrition care plus exercise advice, and the other gets the same plu…

This study tests whether virtual reality (VR) guided imagery can reduce pain in people with stage III or IV breast cancer. Ninety participants will be split into three groups: one using immersive VR (headset), one using non-immersive VR (computer screen), and a control group rece…

This study tests a digital exercise program called EMPOWER for children aged 3 to 6 who are undergoing cancer treatment. The goal is to see if the program can help them stay physically active, improve their motor skills, and boost their quality of life. Parents and nurses will al…

This study tests whether a cannabis extract oil containing THC and CBD can reduce the overall symptom burden in people with advanced solid tumors who are already taking strong painkillers. About 156 participants will receive either the cannabis oil or a placebo for 8 weeks. The m…

This study tests whether a 6-month supervised home exercise program is feasible and safe for adult cancer patients. Participants will cycle and do resistance training three times a week at home, with regular supervision from a physiotherapist. The goal is to see if patients can s…

This study tests whether an online sexual health video series can help women newly diagnosed with breast cancer feel more confident talking to their doctors about sexual health. About 200 women will be randomly assigned to watch the videos or receive usual care. Researchers will …

This study tests whether a personalized exercise program, tracked by a smartwatch, can help reduce fatigue in people who have finished chemotherapy for certain cancers (breast, colorectal, ovarian, pancreatic, or gastric). About 98 participants will be randomly assigned to either…

This study tests whether a simple home exercise program done for at least three weeks before breast cancer surgery can help women recover better. 54 women with early-stage breast cancer will be randomly assigned to either the exercise program or usual care. Researchers will measu…

This study tests whether a personalized diet can improve quality of life in 100 women with advanced gynecologic or breast cancer who are receiving antibody-drug conjugate therapy. Participants will either follow a diet tailored to their needs or receive general Mediterranean diet…

This study tests whether a virtual exercise program with peer support helps older adults (60+) with cancer become more active and feel better. Participants are matched with a peer and receive guidance from exercise professionals or just peer support, compared to usual care. Over …

This study tests a flexible palliative care program for people with advanced heart failure or certain cancers. The program adds more team members—like a social worker or nurse—as symptoms get worse. The goal is to improve quality of life and match care to each person's changing n…

This study tests whether a handheld palm stimulator can reduce pain, fear, and anxiety when cancer patients get an IV for chemotherapy. About 90 adults will be randomly assigned to either squeeze the device during the procedure or receive standard care. The goal is to provide a l…

This study tests a 6-month online program for women with newly diagnosed breast cancer. The program includes daily exercise, mindfulness, and support via email and optional group sessions. Researchers want to see if it reduces psychological distress and improves well-being compar…

This study collects spinal fluid, blood, saliva, and tumor samples from 139 adults with HER2-positive or triple-negative breast cancer that has spread to other organs but not yet to the brain. Researchers will analyze these samples for tumor DNA that might predict when the cancer…

This study tests whether a culturally tailored program can help Black women keep their mammogram appointments. About 176 women aged 40 and older who are scheduled for a screening mammogram will take part. The goal is to find better ways to reduce racial disparities in breast canc…

This observational study is investigating whether a blood marker called GLP-2 could help predict the risk and severity of acute radiation enteritis—a common and painful side effect of radiation therapy to the abdomen or pelvis. Researchers will measure GLP-2 levels in 50 adults b…

This observational study looks at whether different molecular subtypes of breast cancer—like Luminal A, HER2-enriched, and triple-negative—show distinct patterns of bone metastasis on bone scans. Researchers will compare imaging results from 100 adults with breast cancer to see i…

This study tests whether a short educational presentation about radon can improve knowledge and encourage testing among cancer survivors, their caregivers, and family members. Participants attend a single session, either in person or online, led by a study staff member. The goal …

This study tests a digital tool called ReSPECT that helps teens and young adults with cancer talk to their doctors about sexual and reproductive health. The tool includes a pre-visit checklist and an informational website. Researchers want to see if it is practical and helpful fo…

This study investigates how providing information about uncertainties in new cancer drugs' benefits influences patients' hypothetical treatment decisions and perceptions. Researchers will present current or former cancer patients with a scenario about a new drug called Zenova, wh…

This study tests whether sending automated messages to cancer patients after they leave the hospital can help them use urgent oncology care instead of the emergency room. About 200 patients will receive reminders via MyChart and text in English or Spanish. Researchers will track …

This pilot study tests whether surgeons will use a new set of timeline-specific guidelines designed to improve functional recovery after high-risk abdominal cancer surgery. Researchers will monitor how often surgeons follow the guideline in clinic. The goal is to see if such a to…

This study asks whether adding overall survival data to standard progression-free survival information helps current or former cancer patients more accurately judge a new drug's survival benefit. Around 3,000 U.S. adults with a past or present cancer diagnosis will read about a h…

This study looks at how a special program, called the Geriatric Surgery Verification Program, works at the James Cancer Hospital. The program helps doctors and nurses better care for patients aged 65 and older who need cancer surgery. It includes checking for age-related issues l…

This study will collect data from up to 10,000 cancer patients across Europe to create better tools for predicting heart damage caused by certain cancer treatments. Researchers will use artificial intelligence alongside standard methods to develop risk scores that doctors can use…

This study will enroll 235 women with hormone receptor-positive, HER2-negative breast cancer who are taking abemaciclib after surgery. Researchers want to see if higher levels of the drug in the blood are linked to severe diarrhea, a common side effect. By understanding this link…

This study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…

This study explores whether cancer patients undergoing treatment can use a smartwatch and smartphone surveys to report their quality of life and physical activity. Over 12 weeks, participants wear a smartwatch at least 10 hours a day and complete questionnaires at several time po…

This study enrolls 1,000 adults with solid tumors, including breast cancer, who receive an AI-based pathology test as part of their routine care. Researchers will link the AI test results with short- and long-term health outcomes to see how well the scores predict prognosis and t…

This study investigates whether different types of exercise can help middle-aged women reduce their body burden of PFAS (environmental chemicals) and improve muscle function. Participants will be assigned to either interval walking or high-intensity circuit training for six month…

This study looks at how the health of older adults with cancer affects the quality of life of the people who care for them. Researchers will follow 116 patient-caregiver pairs for six months, using questionnaires to measure caregiver well-being and patient frailty. The goal is to…

This study observes people with a common type of advanced breast cancer (HR+/HER2-) who are already on standard hormone therapy. Researchers use simple blood tests to look for changes in the ESR1 gene, which can make the cancer stop responding to treatment. By tracking these muta…

This study tests an AI-powered chatbot that automatically creates personalized survivorship care plans for adult cancer survivors. The chatbot uses information from electronic health records to generate a plan and answer patients' questions about it. Researchers want to see if th…

This pilot study looks at how different resistance training routines change levels of myokines—molecules released by muscles during exercise—in women who have finished breast cancer treatment. Participants will be assigned to one of three exercise regimens (conditioning, strength…

This study uses online surveys to explore whether cancer patients and their family members across the European Union have equal access to mental health screening and psychological support. Researchers will analyze responses from 2,000 participants to identify disparities, barrier…

This study collects health data from Apple Watches and iPhones of 1,200 cancer patients to build a research database. The goal is to see if wearable data like activity and heart rate can help personalize cancer prognosis and treatment. Participants must have an Apple Health app a…

This study is developing an artificial intelligence system that measures changes in total tumor volume from CT or MRI scans to see if it can predict survival better than the current standard method, which measures just a few tumors. Researchers will analyze data from about 6,000 …

This study investigates whether adding environmental exposure risk assessments to standard care is useful and acceptable for women at average or high risk of breast cancer, as well as those diagnosed with early-onset breast cancer. Researchers will survey patients and providers a…

This study is developing an AI tool that analyzes tumor images, proteins, and patient data to predict whether a person with advanced HER2-positive or low-expression breast cancer will benefit from the targeted drug T-DXd. The goal is to avoid giving ineffective treatment, which c…

This study collects blood samples from people with cancer or at high risk for cancer to create a large, well-organized repository for research. The goal is to provide scientists with a valuable resource to study cancer through liquid biopsies, which may lead to better detection a…

This study looks at how well a chemotherapy and immunotherapy combination works for early triple-negative breast cancer when the usual anthracycline drugs are left out. The researchers are focusing on patients who cannot take anthracyclines due to previous treatment, older age, o…

This study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…

This study looks at whether a person's body composition—like muscle mass and body fat—affects how accurately they are positioned during radiation therapy. Researchers will measure body composition in 120–150 cancer patients before and during treatment, and track daily positioning…

This study will survey 370 adult cancer patients about their knowledge, attitudes, and practices regarding physical exercise. The goal is to understand why many patients don't exercise enough and what barriers they face. Results will help create better exercise programs and possi…

This study looks at whether a blood test can predict how well the drug deruxtepruzumab works in people with advanced breast cancer that has low or ultra-low levels of a protein called HER2. Researchers will track cancer cells and HER2 levels in the blood of 100 patients during tr…

This study will observe 200 cancer patients who are already receiving immunotherapy (immune checkpoint inhibitors) along with radiotherapy. Researchers want to see how long the cancer stays under control and how patients fare overall, in everyday clinical practice rather than a s…

This study looks at whether tracking tumor DNA in the blood (ctDNA) can help doctors see how well breast cancer treatment is working before surgery. It will include 186 people with stage II-III HER2-positive or triple-negative breast cancer. Researchers will take blood samples at…

This study looks at how feeling overwhelmed by information and dealing with symptoms affects the sense of empowerment in 300 adult cancer patients getting outpatient chemotherapy. Researchers will use surveys to measure information overload, symptom severity, and empowerment leve…

This study will collect data from 500 cancer patients who are about to start immunotherapy. Researchers want to build a tool that can predict survival outcomes based on factors like combination treatments. The goal is to help doctors and patients make more informed decisions abou…

This study will enroll 56 women with breast cancer to see if two different regional anesthesia techniques (paravertebral block vs. erector spinae plane block) cause different immune responses during surgery. Participants will receive one of the two blocks along with general anest…

This study tracks how the experimental drug AZD1390 moves through and leaves the body after a single dose. It involves about 8 adults with advanced solid tumors who are not currently on active cancer treatment. By using a tiny radioactive label, researchers can measure the drug i…

This study tests whether taking omega-3 supplements before surgery can change the types of fats found in breast tumors. About 35 adults with early-stage breast cancer will take the supplement for 4 to 28 weeks while also receiving standard cancer treatments. The goal is to see if…

This study will test whether whole-body MRI scans and blood tests for tumor DNA can better detect cancer progression in a type of breast cancer that is often missed by standard scans. Researchers will follow 43 people with metastatic invasive lobular carcinoma for up to 30 months…

This study looks at the best ways to add supervised exercise programs into standard cancer care. Researchers will track how often doctors refer patients to exercise and how many patients take part. The goal is to see if this approach is practical and helps improve patients' physi…

This study tests a new chatbot designed to help cancer patients and their caregivers in rural areas find clear information about insurance, travel costs, and other financial aspects of cancer care. About 60 participants will be randomly assigned to use either a hybrid chatbot or …

This large observational study will follow 4,000 young cancer survivors (ages 15-39) across Europe to understand how different cancer treatments impact fertility, hormone function, and pregnancy outcomes. Researchers will also evaluate the safety and success of fertility preserva…

This study will follow 3,000 young women (ages 15-39) with cancer to understand how treatments like chemotherapy and immunotherapy impact their fertility, pregnancy outcomes, and quality of life. Researchers will also look at the safety and success of fertility preservation metho…

This study will test an artificial intelligence system designed to give early warning of cancer spreading to other parts of the body. Current imaging can only see larger tumors, but this AI analyzes routine scans and patient data to detect signs of microscopic spread. Researchers…

This study follows 1,000 young men (ages 15-39) diagnosed with cancer to understand how treatments affect their fertility and hormone levels over time. Researchers will collect medical history, semen samples, and blood tests before and after therapy to identify who is at risk for…

This phase 2 trial is testing whether blood tests and imaging scans can tell if chemotherapy is working in people with early-stage triple-negative breast cancer before they go to surgery. The study will enroll 200 participants who will receive a combination of chemotherapy drugs …

This study is testing a new tool to help older adults (65+) with metastatic breast cancer and their care partners make treatment decisions together. Researchers want to see if the tool is acceptable, appropriate, and practical for use. The study involves 150 participants and focu…

This study looks at tumor samples from 55 women with early-stage breast cancer to find early signs of whether chemo-immunotherapy is working. By analyzing individual cells before, during, and after treatment, researchers hope to identify markers that predict response or resistanc…

This study will survey about 950 men who stored sperm at a French fertility center before cancer treatment between 2010 and 2024. Researchers want to know how many later became fathers, whether naturally or with medical help, and if they used their frozen sperm. The goal is to be…

This study aims to understand why breast cancer in young women is often more aggressive. Researchers will look at how pregnancy and breastfeeding might influence the disease. They will collect information from 1,000 women aged 45 or younger (and a comparison group aged 55+) with …

This study will track muscle deterioration in about 40 hospitalized cancer patients using simple tests like grip strength, electrical muscle readings, and body composition scans. Researchers hope to find patterns that help identify muscle loss early, which could lead to better su…

This study will review medical records of about 240 adults in Kazakhstan with HER2-positive metastatic breast cancer to see how they were treated and how well they did. Researchers will look at treatments given in routine care (except one specific drug) and track outcomes like ho…

This pilot study tests whether a biology-guided therapy recommendations report can help doctors choose treatments for advanced hormone receptor-positive breast cancer that cannot be removed by surgery or has spread. Researchers will analyze tumor tissue from 20 patients to create…

This study will follow 2,200 young women (aged 40 or younger) who had breast cancer and carry a mutation in a breast cancer gene other than BRCA1/2. Researchers want to see if getting pregnant after diagnosis affects the cancer's return. The study does not test any drug or treatm…

This early-stage study looks at whether taking oral paclitaxel with encequidar on an empty stomach or after a meal changes how much drug gets into the body. About 46 adults with advanced solid tumors (like breast, lung, or stomach cancer) will take the drugs in different sequence…

This study tests whether a new collimator (a filter that directs gamma rays) on a special camera can produce clearer whole-body images for cancer patients. About 18 adults with multiple known cancer lesions will receive standard scans using technetium-99m, lutetium-177, or iodine…

This study looks at how gut bacteria affect diarrhea and other stomach issues in people with HR+/HER2- breast cancer taking the drug abemaciclib. In the first part, researchers will collect stool samples to track bacteria changes. In the second part, a small group will try eating…

This study aims to understand what might cause breast cancer in men by collecting genetic, environmental, and lifestyle information from 120 male volunteers who are relatives of male breast cancer patients. Participants will fill out a questionnaire and provide a blood sample for…

This study surveys 240 breast cancer patients to understand how they use herbs and supplements alongside standard treatments like chemo or hormone therapy. Researchers want to see if ethnicity influences which products people take. The goal is to gather information, not to test a…

This study looks at women with a very early form of breast cancer called DCIS. It uses a special test to find those at low risk of the cancer coming back. The goal is to see if these low-risk women can skip radiation therapy after their lump-removal surgery without a meaningful i…

This study looks at how diet and gut bacteria affect treatment outcomes in women with early-stage triple-negative breast cancer. Researchers will collect stool, blood, and tumor samples from 300 participants before, during, and after chemotherapy and immunotherapy. The goal is to…

This study looks at how platinum-based chemotherapy can cause permanent hearing loss in cancer patients, and whether people from poorer backgrounds are more affected. Researchers will test hearing and thinking skills in 172 patients from North West England before and after treatm…

This observational study will interview 10 to 20 adults receiving chemotherapy as outpatients at a Turkish hospital. Researchers want to understand how patients perceive nursing care that is tailored to their individual needs, values, and lifestyle. The goal is to identify what m…

This study looks at how adults getting chemotherapy use digital media and how well they understand online health information. Researchers will survey 80 patients about their digital habits and health literacy. The goal is to learn more so doctors can better support patients in us…

This study looks back at medical records of 2000 women with HER2-positive early breast cancer who still had cancer after initial treatment. Researchers want to see which follow-up drug regimen—trastuzumab plus pertuzumab or T-DM1—leads to better long-term outcomes. The goal is to…

This study will collect data from 500 Danish cancer patients who need repeat radiation therapy (reirradiation). Researchers will track side effects, tumor control, and survival to build a database that can guide safer treatment in the future. The goal is to help doctors decide wh…

This study will follow 75 women aged 18-42 with early-stage triple-negative breast cancer who are receiving chemotherapy plus immunotherapy before surgery. Researchers will measure hormone levels, track menstrual patterns, and use questionnaires to see how treatment affects ovari…

This study aims to find blood markers that can predict which cancer patients will develop chronic nerve pain from chemotherapy. Researchers will collect blood samples and perform neurological exams on 192 patients over 6 months. The goal is to use this information to personalize …

This study looks back at data from 201 people with triple-negative breast cancer who received chemotherapy or immunotherapy before surgery. The goal is to compare how often the cancer completely disappears after treatment and find out what factors influence success. This is an ob…

This study looks at whether tiny particles called exosomes, released by breast cancer cells, contain genetic material (microRNA) that can predict how well chemotherapy will work before surgery. Researchers will collect tumor tissue and blood samples from 60 women with breast canc…

This observational study will follow 300 women aged 45-55 with hormone receptor-positive breast cancer to see if changes in a hormone called AMH can predict when they will reach menopause. Researchers will collect blood samples at seven time points and track menstrual patterns. T…

This study will test an AI-powered tool that analyzes tumor samples to help doctors choose the best treatment for people with triple-negative breast cancer. The tool looks at immune cells in the tumor to predict how well chemotherapy might work. The goal is to see if the tool can…

This study checks if a short questionnaire called G8 can correctly identify frailty in people aged 70 and older with solid tumors. Researchers will compare the G8 results with a full geriatric assessment in 150 patients. The goal is to see if the G8 tool works well for Portuguese…

This study aims to create a simple tool (called a nomogram) that predicts the chance of breast cancer coming back in women with HR+/HER2- early-stage breast cancer. Researchers will look back at the records of 500 patients to find patterns that help personalize risk estimates. Th…

This study observes 400 adults with advanced HER2-negative breast cancer who have already received antibody-drug conjugates. Researchers will track how long patients stay cancer-free or alive after starting eribulin-based therapy. The goal is to understand real-world treatment ou…

This study looks for biological markers in tumor tissue and blood that may be linked to anxiety and depression in people with solid tumors. Researchers will combine psychological assessments with lab tests to better understand these emotional struggles. The goal is to improve ear…

This study looks at 150 breast cancer patients starting T-DXd, a drug that often causes nausea, vomiting, and weight loss. Researchers will measure blood levels of a hormone called GDF-15 before and during treatment to see if changes in GDF-15 are linked to these side effects. If…

This observational study looks at how having type 2 diabetes impacts quality of life in cancer patients receiving immunotherapy. Researchers will compare changes in well-being over six months between patients with and without diabetes. About 920 adults with solid tumors will fill…

This study will follow 81 people with early-stage, hormone-positive breast cancer who are at high risk of the cancer coming back. Researchers want to see how often patients take their prescribed CDK4/6 inhibitor pills (abemaciclib or ribociclib) alongside standard hormone therapy…

This study will compare two different tissue expanders used in breast reconstruction after mastectomy in 80 women. Some participants will also receive radiation therapy, which is not typically recommended with these devices. Researchers will evaluate aesthetic outcomes, patient s…

This study looks at whether doing broad gene testing early, instead of later, helps find more effective treatments for people with advanced pancreatic, liver, or triple-negative breast cancer. About 360 adults with poor-prognosis cancers will be randomly assigned to early or stan…

This study will track gut microbiome changes in 12 women with hormone receptor-positive breast cancer starting Verzenio (abemaciclib) therapy. Participants will take either a resistant potato starch supplement or a placebo, and provide stool samples and symptom questionnaires rem…

This study aims to better understand psychiatric disorders, thinking problems, and treatment side effects in 2000 cancer patients and their close relatives. Researchers will compare those with and without mental health issues to find patterns and improve care. No new treatments a…

This study will test a new AI tool called BaiXiaoAi that helps cancer patients, their families, and their doctors stay connected. About 300 adults with cancer will join a special WeChat group where the AI answers questions and shares helpful information. The goal is to see if the…

This study will test a remote monitoring platform designed to help cancer patients who face barriers like language or lack of insurance. About 50 adults with cancer will use the platform at home to track symptoms and communicate with their care team. The goal is to see if the pla…

This study will test a new way to offer vaccines to vulnerable patients—those with chronic diseases or weakened immune systems—during hospital visits. Researchers will see if offering, prescribing, and giving vaccines in the hospital increases how many people get vaccinated. The …